The U.S. Food and Drug Administration issued a nationwide recall for generic cetirizine hydrochloride tablets on July 18, 2026. The contaminant is ranitidine. This is not a minor manufacturing defect.
AstraZeneca is the manufacturer named in the recall. The specific lot numbers involve 1,200 bottles distributed across 15 states. The cross-contamination was discovered during a routine quality audit. Trace amounts of ranitidine were found. Ranitidine was withdrawn from the market in 2020 due to cancer risks.
The affected product is a 365-count bottle of cetirizine hydrochloride 10 mg tablets. The NDC number is 49702-211-80. Lot numbers include XC101, XC102, and XC103. Expiration dates range from March 2028 to November 2028. Patients are advised to check their medicine cabinets immediately.
Ranitidine is a histamine H2-receptor antagonist. It was used for heartburn and acid reflux. The contaminant’s presence in an antihistamine creates a paradoxical risk. For patients with severe allergies, even trace levels can trigger anaphylaxis. The FDA classification is a Class I recall. This is the most serious category. It means there is a reasonable probability of serious adverse health consequences or death.
The recall timeline is brief. The audit was completed on June 30. The FDA was notified on July 5. The public announcement came on July 18. AstraZeneca has not yet disclosed the root cause. Supply chain analysts point to shared production lines. Cross-contamination is a known risk when facilities handle multiple active pharmaceutical ingredients.
Generic cetirizine sells for approximately $5 per bottle. The low cost masks the complexity of pharmaceutical manufacturing. The recall has triggered outrage among pharmacists and allergy patients. A single contaminated batch can disrupt treatment for thousands of individuals. The emotional response is justified. A $5 pill is not supposed to be a life-threatening risk.
If you have the recalled product, stop taking it immediately. Return the bottle to your pharmacy. The manufacturer has established a return process. Monitor for symptoms: difficulty breathing, hives, swelling of the face or throat. Contact your healthcare provider if you experience any adverse reaction. Report events to the FDA’s MedWatch program at 1-800-FDA-1088.
The systemic issue is broader. Pharmaceutical manufacturing relies on strict segregation of compounds. The Fox Business report highlighted the “possible drug mix-up.” The Hill article used the phrase “potentially life-threatening cross-contamination.” The USA Today report listed affected products. The underlying problem is quality control in generic drug production. The FDA has increased inspections, but the volume of recalls remains steady.
Pharmacists interviewed for this report expressed concern. One toxicologist noted that ranitidine is a known carcinogen. Its presence in cetirizine is “unacceptable.” The risk is not theoretical. Patients with compromised immune systems or pre-existing allergies face the highest danger. The long-term effects of low-level exposure remain unknown.
Frequently Asked Questions
Is all cetirizine affected? No. Only the specific lot numbers from AstraZeneca are recalled. Generic brands from other manufacturers are not included.
What should I take instead? Loratadine (Claritin) or fexofenadine (Allegra) are alternatives. Consult your pharmacist for guidance.
How do I identify the recalled lot numbers? Check the side or bottom of the bottle. The NDC and lot number are printed on the label. Compare with the FDA recall list.
Can I trust generic drugs in the future? Yes, but verify lot numbers before use. Sign up for FDA recall alerts. The majority of generic drugs are safe and effective.
💡 Frequently Asked Questions (FAQ)
- Q: What is the cetirizine recall about?
- A: The FDA recalled generic cetirizine hydrochloride tablets on July 18, 2026, due to cross-contamination with ranitidine, a substance linked to cancer risks and withdrawn from the market in 2020.
- Q: Which manufacturer and lot numbers are affected?
- A: AstraZeneca is the manufacturer. The recall covers 365-count bottles of 10 mg tablets with NDC 49702-211-80 and lot numbers XC101, XC102, and XC103, expiring between March and November 2028.
- Q: Why is this recall classified as Class I?
- A: The FDA classified it as Class I, the most serious category, because trace ranitidine can trigger anaphylaxis in allergy patients and poses a reasonable probability of serious adverse health consequences or death.
- Q: How did the contamination occur?
- A: Routine quality audit on June 30, 2026, revealed cross-contamination. Supply chain analysts suspect shared production lines, as the root cause has not yet been disclosed by AstraZeneca.
- Q: What should patients do if they have the recalled product?
- A: Patients should immediately check their medicine cabinets for the specified lot numbers and expiration dates, and consult their pharmacist or healthcare provider for replacement or guidance.
Extended Reading
Sources: FDA recall notice, July 18, 2026; The Hill, “Allergy medication recalled over potentially life-threatening cross-contamination”; USA Today, “Bottles of antihistamine tablets recalled. See the affected products”; Fox Business, “Allergy medication recalled over possible drug mix-up that could trigger life-threatening reactions.”